We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease (ADVISe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04576793
Recruitment Status : Recruiting
First Posted : October 6, 2020
Last Update Posted : September 19, 2022
Sponsor:
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
James M Noble, MD, MS, CPH, FAAN, Columbia University

Brief Summary:

The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer's disease to participate. This includes patients with either:

  • Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties
  • Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties
  • Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties
  • The investigators are also enrolling older adults with normal visual, language, and memory function.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: 11C-ER176 Drug: 18F-MK6240 Drug: 18F-Florbetaben Procedure: Lumbar Puncture Phase 2

Detailed Description:

This study is being done to learn about inflammation in Alzheimer's disease so that the investigators can find out new ways to treat patients with this disease. Because Alzheimer's disease usually causes slow changes to the brain over time, in this study the investigators are going to perform different tests and then repeat some of them two years later.

Inflammation can be measured using a type of brain scan called a positron emission tomography (PET) scan. A PET scan uses very small amounts of a radioactive drug that is injected into a vein to create a special picture of the brain. The inflammation PET scan uses a drug called ER176. ER176 is an experimental drug but has been used in several human studies before. Once in the body, ER176 sticks to areas with lots of inflammation, and the PET scan allows us to see these areas.

Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators need to perform a lumbar puncture (spinal tap). Certain genes that inherited from parents influence the amount of inflammation in the body. The investigators can study how genes affect inflammation in Alzheimer's disease by looking doing genetic tests on blood that collected from the vein.

The investigators can study how genes affect inflammation in Alzheimer's disease by doing genetic tests on blood. The investigators will also be testing blood for severe acute respiratory syndrome (SARS)- CoV-2 (the virus that causes COVID-19) antibodies. The investigators want to see if exposure to the virus that causes COVID-19 changes the amount of inflammation in the brain or not.

Along with inflammation, Alzheimer's disease is also associated with the build up of the proteins amyloid and tau in the brain. The investigators can measure these proteins using PET scans. The amyloid PET scan uses a drug called florbetaben that has been approved by the FDA to help diagnose Alzheimer's disease. The tau PET scan uses a drug called MK-6240. Like ER176, MK-6240 is experimental but has been used in several human studies before.

A brain MRI creates a high resolution picture of the brain. The brain MRI helps the investigators get more information from the PET scans, and can also tell the investigators the size and appearance of different brain structures. When someone has Alzheimer's disease, some of these brain structures get smaller or have altered appearance on MRI.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease
Actual Study Start Date : November 17, 2020
Estimated Primary Completion Date : May 31, 2025
Estimated Study Completion Date : May 31, 2025


Arm Intervention/treatment
Experimental: Cognitive impairment
  • Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties
  • Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties
  • Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties
Drug: 11C-ER176
11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
Other Name: [11C] ER176

Drug: 18F-MK6240
MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
Other Name: [18F-MK6240]

Drug: 18F-Florbetaben
Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
Other Name: [18F] Florbetaben

Procedure: Lumbar Puncture
Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
Other Name: Spinal Tap

Active Comparator: No cognitive impairment
Healthy controls
Drug: 11C-ER176
11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
Other Name: [11C] ER176

Drug: 18F-MK6240
MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
Other Name: [18F-MK6240]

Drug: 18F-Florbetaben
Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
Other Name: [18F] Florbetaben

Procedure: Lumbar Puncture
Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
Other Name: Spinal Tap




Primary Outcome Measures :
  1. 11C-ER176 Standardized Uptake Value Ratio [ Time Frame: Up to 24 months ]
    The standardize uptake value ratio is the concentration of radioactivity measured from the 11C-ER176 PET scan in the cortex compared to the uptake in the cerebellum (pseudo-reference region).

  2. 18F-MK6240 Standardized Uptake Value Ratio [ Time Frame: Up to 24 months ]
    The standardize uptake value ratio is the concentration of radioactivity measured from the 18F-MK6240 PET scan in the cortex compared to the uptake in the cerebellum (pseudo-reference region).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  1. Age 50 and over at time of screening.
  2. At screening, must have no cognitive impairment, or meet criteria for amnestic Alzheimer's disease, posterior cortical atrophy, or logopenic variant primary progressive aphasia. Diagnoses will be made based on history, exam, neuropsychological testing, brain MRI, and consensus diagnosis.
  3. Patients must have Clinical Dementia Rating scale score of 0.5 or 1 at enrollment. Controls must have Clinical Dementia Rating scale score of 0 at enrollment.
  4. Subjects unable to provide informed consent must have a surrogate decision maker.
  5. Written and oral fluency in English.
  6. Able to participate in all scheduled evaluations and to complete all required tests and procedures.
  7. In the opinion of the PI, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.

Exclusion criteria:

  1. Past or present history of a brain disorder other than Alzheimer's disease (including presence of cortical infarct on MRI even in absence of clinical stroke).
  2. Serious medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries.
  3. Contraindication to MRI scanning.
  4. Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.).
  5. Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits.
  6. Participation in the last year in a clinical trial for a disease modifying drug for AD.
  7. Taking immunosuppressive medication (e.g., glucocorticoids, cytostatics, antibodies, drugs acting on immunophilins, interferons, tumor necrosis factor inhibitors). Nonsteroidal anti-inflammatory drugs (NSAIDs) are not exclusionary.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04576793


Contacts
Layout table for location contacts
Contact: Galen Ziaggi 212-305-9079 gfz2102@cumc.columbia.edu
Contact: Elena M. Golub 212-305-9079 eg2972@cumc.columbia.edu

Locations
Layout table for location information
United States, New York
Columbia University Irving Medical Center Recruiting
New York, New York, United States, 10032
Contact: Aubrey S. Johnson    212-305-9079    aj2842@cumc.columbia.edu   
Sponsors and Collaborators
James M Noble, MD, MS, CPH, FAAN
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: James M. Noble, MD, MS Columbia University
Layout table for additonal information
Responsible Party: James M Noble, MD, MS, CPH, FAAN, Associate Professor of Neurology, Columbia University
ClinicalTrials.gov Identifier: NCT04576793    
Other Study ID Numbers: AAAS7810
R01AG063888 ( U.S. NIH Grant/Contract )
First Posted: October 6, 2020    Key Record Dates
Last Update Posted: September 19, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data will be available upon reasonable request from a qualified investigator.
Time Frame: Up to two weeks after review and approval of request.
Access Criteria: Investigator qualifications and previous work will be reviewed by PI. Subsequent email correspondence will relay technical criteria needed for access.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by James M Noble, MD, MS, CPH, FAAN, Columbia University:
Inflammation
PET scans
Cognitive Impairment
Posterior Cortical Atrophy
Logopenic Variant Primary Progressive Aphasia
Amnestic Alzheimer's Disease
MK-6240
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders